AKT1 and neoplasm: The core components of this pathway, namely PI3Ks, AKT, and mTOR, have been extensively studied and found to be frequently hyperactivated in several human cancers, and their inhibition has been shown to lead to tumor regression in many preclinical studies [32,33].